Literature DB >> 15334052

Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogenic hematopoietic stem cell transplantation in Philadelphia-positive leukemias.

M Tiribelli, L Marin, E Calistri, A Geromin, D Damiani, R Fanin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15334052     DOI： 10.1038/sj.bmt.1704687

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  2 in total

1.  Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial.

Authors:  Josep-Maria Ribera; Albert Oriol; Marcos González; Belén Vidriales; Salut Brunet; Jordi Esteve; Eloy Del Potro; Concepción Rivas; Maria-José Moreno; Mar Tormo; Victoria Martín-Reina; Josep Sarrá; Ricardo Parody; Jaime Pérez de Oteyza; Encarna Bureo; Maria-Teresa Bernal
Journal:  Haematologica       Date:  2009-10-01       Impact factor: 9.941

2.  Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis.

Authors:  H J Khoury; M Kukreja; J M Goldman; T Wang; J Halter; M Arora; V Gupta; D A Rizzieri; B George; A Keating; R P Gale; D I Marks; P L McCarthy; A Woolfrey; J Szer; S A Giralt; R T Maziarz; J Cortes; M M Horowitz; S J Lee
Journal:  Bone Marrow Transplant       Date:  2011-10-10       Impact factor: 5.483
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.